Comparative evaluation of the efficiency of complex bioactive indol and vitex-containing medicines in treatment of dishormonal dysplasia of the mammary glands
Keywords:fibrocystic disease, dishormonal dysplasia of the mammary glands, mastopathy, indole-3-carbinol, epigallocatechin-3-gallat, Epigalin Brest
Purpose of study. Comparison the efficacy of therapy of fibrocystic breast disease (FBD) in women of reproductive age with different complex bioactive indole-containing and vitex-containing drugs.
Materials and methods. The study involved 80 patients with FBD who received Epigalin Brest (Group I, 40 women) and Depapillin (Group II, 40 women). Methods of study included anthropometry, hormonal profile, ultrasound examination of the breast and pelvic organs, mastodin score.
Results and discussion. By ultrasound characteristics diffuse dyshormonal mammary dysplasia was prevalent among patients of Groups I and II. By the degree of severity of mastopathy patients were divided into groups evenly. Hormonal examinations revealed the presence of relative hyperestrogenia, hypoprogesteroneemia and transient hyperprolactinemia. Three months later a complete reduction in pain was obtained in 70.0% patients of Group I and 37.5% of Group II. After 6 months 90.0% patients of Group I and 75.0% patients of Group II noted the absence of mastalgia. Positive ultrasound changes after a three-month course of therapy in 81.8% patients of Group I with diffuse mastopathy with predominance of the glandular component and 73.7% of Group II were characterized by the lack of visualization of hypertrophied glandular lobules, enlarged milk ducts, but complete months only occurred in patients of Group I (100.0%).
Conclusions. A comparative study demonstrated the high efficacy of the complex bioactive drug Epigalin Brest: clinical efficacy with complete reduction of pain in 70.0% patients after three months and 90.0% after six months of therapy. The undeniable advantages of Epigalin Brest are the presence of 3,3-diindolylmethane, which is a finished product of indole-3-carbinol conversion, characterized by higher bioavailability and stability, which provides a pronounced clinical effect and a clear dosage of epigallocatechin-3-gallate.
- Andreeva, E.N., Khamoshina, M.B., Rudneva, O.D. “Prolactin and mammary glands: norm and pathology.” Gynecology 1 (2012): 12–6.
- Ashrafyan, L.A., Babaeva, N.A., Antonova, I.B., et al. “The level of estrogen metabolites balance in breast cancer and ways to its’ correct.” Tumors of the Female Reproductive System 3 (2015): 22–9. DOI: 10.17 650/1994-4098-2015-11-3-22-29
- Bespalov, V.G., Travina, M.L. “Fibro-cystic disease and risk of breast cancer (literature review).” Tumors of the Female Reproductive System 4 (2015): 58–70.
- Vuttke, V., Zaydlova-Vuttke, D., Jarri, G., Artymuk, N. “The role of Vitex agnus-castus in gynecological endocrinology.” Ginekology 14.1 (2011): 4–7.
- Kedrova, A.G., Levakov. S.A. “Phytopreparations in the treatment of gynecological patients with severe mastalgia.” Tumors of the Female Reproductive System 13.4 (2017): 63–70.
- Radzinsky, V.E., Ordiyants, I.M., Maslennikova, M.N., Pavlova, E.A. “Mammary glands and gynecological diseases: from a community of pathogenetic views to practical solutions. Health options for women with a combination of uterine fibroids and benign breast dysplasias.” Women's health 6.112 (2016): 104–9.
- Rozhkova, N.I., Burdina, I.I., Zapirova, S.B., et al. “Timely treatment of diffuse hyperplasia: prevention of breast cancer.” Onkoginekology 1 (2016): 4–11.
- Simonovskaya, H.Y., Ryzhova, T.E. “Phytopreparations in the treatment of benign and malignant diseases of the mammary glands.” StatusPraesens. Ginekology, Obstetrics. Sterile marriage 4.40 (2017): 89–97.
- Tatarchuk, T.F., Kalugina, L.V. “On the prevention and treatment of hormone-dependent hyperproliferative diseases in women.” Women's health 7.83 (2013): 51–7.
- “Evaluation of the effectiveness of targeted therapy in women with hyperplastic gynecological syndrome and comorbid pathology.” Reproductive endocrinology 5.31 (2016): 90–6.
- Elakad, E.V., Sotnikova, L.S., Tonkikh, O.S. “Hormonal regulation state in fibrocystic mastopathy.” Mother and Child on Kuzbass 1 (2011): 342–6.
- Auborn, K.J., Fan, S., Rosen, E.M., et al. “lndole-3-carbinol is a negative regulator of estrogen.” J Nutr 133 Suppl 7 (2003): 2470–5.
- Brandi, G., Paiardini, M., Cervasi, B., et al. “A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.” Cancer Res 63.14 (2003): 4028–36.
- Dyrstad, S.W., Yan, Y., Fowler, A.M., Colditz, G.A. “Breast cancer risk associated with benign breast disease: systematic review and meta-analysis.” Breast Cancer Res Treat 149.3 (2015): 569–75.
- Firestone, G.L., Bjeldanes, L.F. “lndole-3-carbinol and З-З’-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions.” J Nutr 133.7 (2003): 2448–55.
- Jung, Y.D., Ellis, L.M. “Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (ЕGCG), a major component of green tea.” Int J Exp Pathol 82.6 (2001): 309–16.
- Koçoğlu, D., Kurşun, S., Akin, B., Altuntug, K. “Mastalgia and associated factors: a cross-sectional study.” Agri 29.3 (2017): 100–8. DOI: 5505/agri.2017.91069
- Legeay, S., Rodier, M., Fillon, L., et al. “Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome.” Nutrients 7 (2015): 5443–68.
- Samoli, E., Trichopoulos, D., Lagiou, A., et al. “The hormonal profile of benign breast disease.” Br J Cancer 108 (2013): 199–204. DOI: 10.1038/bjc.2012.493
- Socolov, D., Anghelache, I., Ilea, C., et al. “Benign breast disease and the risk of breast cancer in the next 15 years.” Rev Med Chir Soc Med Nat Iasi 119.1 (2015): 135–40.
- Thomson, C.A., Ho, E., Strom, M.B. “Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies.” Nutr Rev 74.7 (2016): 432–43. DOI: 10.1093/nutrit/nuw010
- ACOG.“The ACOG Practice Bulletin No. 164 Summary: Diagnosis and Management of Benign Breast Disorders.” Obstetrics and gynecology 127.6 (2016): 1181–3.
- Van Die, M.D., Burger, H.G., Teede, H.J., Bone, K.M. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Med 79.7 (2013): 562–75.
- Vigontina, O.G., Efimenko, O.A., Yakovenko, L.F., et al. “Chaperon Hsp-60 as autoantigen in development of dyshormonal breast diseases.” Experimental Oncology 24.2 (2002): 112–5.
How to Cite
Copyright (c) 2019 В. І. Пирогова, С. О. Шурпяк, А. Г. Місюра
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.